Mankind Pharma delivered a strong financial performance for FY26, reporting a revenue of INR 14,278 crore, a 17% YoY increase. The company achieved an adjusted EBITDA margin of 25.4%. Growth was driven by robust performance in the domestic market, particularly in chronic therapies and specialty segments. With a focus on long-term sustainability, Mankind continues to scale its specialty portfolio, bolster its consumer healthcare franchise, and maintain its #1 position in prescription share.
Financial Highlights
Mankind Pharma reported steady growth for the fiscal year ended March 31, 2026. The company’s revenue from operations reached INR 14,278 crore, reflecting a solid 17% year-over-year increase. For the final quarter (Q4 FY26), revenue stood at INR 3,443 crore, a growth of 11.8% YoY. The company maintained strong profitability, with an adjusted EBITDA margin of 25.4% for the full year and 27.1% for Q4 FY26.
Domestic Market and Specialty Growth
Domestic business remains the cornerstone of Mankind’s operations, contributing 86% of total revenues in FY26. Domestic revenue grew by 14.4% for the year to INR 12,217 crore. A key driver of this success has been the company’s strategic focus on chronic therapies, with chronic share in the total portfolio rising to approximately 39%. The performance was supported by strong double-digit growth in cardiac and anti-diabetes segments, alongside successful expansion in super-specialty portfolios through strategic acquisitions.
Consumer Healthcare Momentum
The consumer healthcare (OTC) business demonstrated significant momentum, growing 20% YoY in Q4 FY26. This segment benefited from strong brand recall and an increasing presence in e-commerce and modern trade, which now represents 13% of total consumer healthcare business in FY26. Key brands such as Manforce, Prega News, and Gas-o-fast continue to hold leadership positions in their respective categories.
Future Outlook and Strategic Priorities
Looking ahead, Mankind Pharma is committed to sustaining its growth trajectory by focusing on deepening market penetration in metro and Tier-1 cities and scaling up its specialty and super-specialty brands. The company aims to leverage AI/ML-based technologies to enhance productivity and evidence-based marketing. Furthermore, Mankind remains dedicated to operational excellence, with a strong commitment to sustainability goals, including achieving 100% renewable power usage by FY30 and maintaining high standards in occupational health and safety.
Source: BSE
